ATLANTA, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months ended September 30, 2017. "Earlier this week we were pleased to announce the culmination of our strategic review process with the signing of a definitive merger agreement with Vaxart, which we believe complements Aviragen's focus on infectious diseases. VXRT Stock Price & Charts | Vaxart Aug 09, 2019 · In depth view into VXRT (Vaxart) stock including the latest price, news, dividend history, earnings information and financials. Biota Pharmaceuticals, Inc. Announces Name Change to ... As Aviragen Therapeutics, we will continue to advance and expand our promising pipeline of anti-viral drugs." The name change become effective on April 11, 2016 and the Company's common stock will begin trading on the NASDAQ Stock Exchange under the new ticker symbol "AVIR" on April 13, 2016.
Discover historical prices for AVIR stock on Yahoo Finance. View daily, weekly or monthly format back to when Aviragen Therapeutics, Inc. stock was issued.
Historical daily share price chart and data for VAXART, INC since 2020 adjusted Vaxart, Inc., formerly known as Aviragen Therapeutics, is based in South San Historical stock splits for Aviragen Therapeutics since 2018. Prices shown are splits or dividends. Please see the "Historical Prices" tab for adjusted price values . Aviragen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of IPO Status Delisted Stock Symbol NASDAQ: AVIR. 18 Mar 2020 Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that
Aviragen Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.10 per share The affirmative vote of the holders of a majority of the shares of Aviragen common stock properly cast at the Aviragen Special Meeting, presuming a quorum is present, is required to approve the proposed merger. risks related to the market price of
18 Mar 2020 Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that 13 Mar 2020 Vaxart, Inc., formerly known as Aviragen Therapeutics, is based in South San Francisco, United States. Company Info. Vaxart Inc. 290 Utah Ave. 2 Nov 2017 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. on the NASDAQ Capital Market under the proposed ticker symbol VXRT. 16 Mar 2020 ]IBIO stock isn't the only equity of its kind whose stock price has surged The stock of Vaxart's predecessor company, Aviragen Therapeutics, Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., Nabi Biopharmaceuticals, Nabi, Nabi and 5 filings. Stock values as filed, not updated for current price. Vaxart Inc - VXRT data available via the Intrinio API. Aviragen Therapeutics, Inc ., a biopharmaceutical company, focuses on the Price to Book, $1.51.
Aviragen Therapeutics Inc. - The New York Times
13 Feb 2018 Closes Merger with Aviragen Therapeutics, Inc. Combined Company Renamed Vaxart, Inc. and Will Begin Trading Under New Symbol NASDAQ:
Aviragen Therapeutics Reports First Quarter of Fiscal Year ...
AVIR / Aviragen Therapeutics, Inc. / SENZAR ASSET MANAGEMENT, LLC Passive Investment. 04-06 sec.gov UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No._____)* Biota Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.10 per share (Title of Class of …
AVIR / Aviragen Therapeutics, Inc. - Institutional ... Aviragen Therapeutics, Inc. (NASDAQ:AVIR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.